DK2262785T3 - Benzofuranderivater som fxr-modulatorer - Google Patents

Benzofuranderivater som fxr-modulatorer Download PDF

Info

Publication number
DK2262785T3
DK2262785T3 DK09731855.4T DK09731855T DK2262785T3 DK 2262785 T3 DK2262785 T3 DK 2262785T3 DK 09731855 T DK09731855 T DK 09731855T DK 2262785 T3 DK2262785 T3 DK 2262785T3
Authority
DK
Denmark
Prior art keywords
benzofuran
carboxylic acid
piperazin
bromo
chloro
Prior art date
Application number
DK09731855.4T
Other languages
English (en)
Inventor
Gisèle Mautino
Ingo Kober
Francis Contard
Serge Christmann-Franck
Saumitra Sengupta
Ramesh Sistla
Rao Gummadi Venkateshwar
Didier Roche
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39769187&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2262785(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK2262785T3 publication Critical patent/DK2262785T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (3)

1. Forbindelser valgt fra gruppen - 4-(4-brom-2-ethoxycarbonyl-benzofuran-5-yl)-piperazin-l-carboxylsyre-tert-butylester - 4-(4-brom-2-carboxy-benzofuran-5-yl)-piperazin-l-carboxylsyre-tert-butylester - 5-[4-(3-methoxy-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 5-[4-(4-methoxy-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 5-[4-(3-Trifluornnethyl-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-annid - 5-[4-(3-chlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 5-[4-(3-fluor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 5-[4-(3-chlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 4-brom-5-[4-(4-methoxy-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 5-(4-benzensulfonyl-piperazin-l-yl)-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-fluor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-chlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-fluor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(pyrrolidin-l-carbonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-chlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-(2-carboxy-benzofuran-5-ylamino)-piperidine-l-carboxylsyre-tert-butylester - 2-[4-(4-brom-2-carboxy-benzofuran-5-yl)-piperazin-l-carbonyl]-pyrrolidin-l-carboxylsyre-tert-butylester - 4-(4-chlor-2-ethoxycarbonyl-benzofuran-5-yl)-piperazin-l-carboxylsyre-tert-butylester - 4-(2-carboxy-4-chlor-benzofuran-5-yl)-piperazin-l-carboxylsyre-tert-butylester - 4-brom-5-[4-(3-trifluormethyl-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(3-methoxy-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-methoxy-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(4-methoxy-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(pyrrolidin-2-carbonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(adamantan-l-carbonyl)-piperazin-l-yl]-4-brom-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-chlor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2-fluor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-fluor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-(4-benzoyl-piperazin-l-yl)-4-brom-benzofuran-2-carboxylsyre - 5-[4-(3,5-difluor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 4-brom-5-[4-(3-trifluormethyl-benzyloxy)-piperidin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-chlor-benzyloxy)-piperidin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2-chlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(4-chlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(4-fluor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2-chlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(4-chlor-benzyl)-piperazin-l-yl)-benzofuran-2-carboxylsyre - 4-brom-5-[4-(pyridin-2-yloxy)-piperidin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-trifluormethyl-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 5-[4-(3-trifluormethoxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 4-brom-5-[4-(3-trifluormethoxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 4-brom-5-[4-(3-cyano-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-(4-tert-butylcarbamoyl-piperazin-l-yl)-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-fluor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 4-brom-5-[4-(3,5-dichlor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 4-brom-5-[4-(3,5-difluor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 4-brom-5-(4-pyndin-3-ylmethyl-piperazin-l-yl)-benzofuran-2-carboxylsyre - 4-brom-5-(4-pyridin-4-ylmethyl-piperazin-l-yl)-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-tnfluormethoxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-phenoxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3,5-dimethoxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(3-allyl-2-hydroxy-benzyl)-piperazin-l-yl]-4-bronn-benzofuran-2-carboxylsyre - 5-(4-benzensulfonyl-piperazin-l-yl)-4-brom-benzofuran-2-carboxylsyre - 4-brom-5-(4-tert-butylcarbamoyl-piperidin-l-yl)-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2-chlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-chlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(4-chlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2-fluor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-fluor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(4-fluor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-trifluormethyl-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-trifluormethoxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(3-carboxy-benzyl)-piperazin-l-yl]-4-chlor-benzofuran-2-carboxylsyre - 4-chlor-5-(4-pyndin-3-ylmethyl-piperazin-l-yl)-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2-chlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-chlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(4-chlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(4-methoxy-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-methoxy-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-fluor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3,5-dichlor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-fluor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-cyano-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2-chlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-amid - 4-brom-5-[4-(3-fluor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-ethoxy-amid - 4-brom-5-[4-(3-trifluormethyl-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-trifluormethoxy-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-methoxy-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2,5-dichlor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3,5-dichlor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2-methyl-l H-benzoimidazol-4-carbonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(5-tnfluormethyl-pyndin-2-yloxy)-pipendin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[l-(3-chlor-benzyl)-piperidin-4-ylannino]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-chlor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2,5-dichlor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-methoxy-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-trifluormethyl-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-tnfluormethoxy-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2-methyl-l H-benzoimidazol-4-carbonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(lH-benzoimidazol-5-carbonyl)-piperazin-l-yl]-4-chlor-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2,5-dichlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3,5-dimethoxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-chlor-phenylmethansulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(2-chlor-benzensulfonyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(3-fluor-benzensulfonyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-(2-carboxy-4-methyl-benzofuran-5-yl)-piperazin-l-carboxylsyre-tert-butylester - 4-(2-carboxy-4-chlor-benzofuran-5-yl)-[l,4]diazepan-l-carboxylsyre-tert-butylester - 4-(4-brom-2-carboxy-benzofuran-5-yl)-[l,4]diazepan-l-carboxylsyre-tert-butylester - 4-brom-5-[4-(2-chlor-benzensulfonyl)-[l,4]diazepan-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2-chlor-benzensulfonyl)-[l,4]diazepan-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(5-trifluormethyl-pyridin-2-yloxy)-piperidin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[l-(3-chlor-benzensulfonyl)-piperidin-4-ylannino]-benzofuran-2-carboxylsyre - {4-brom-5-[4-(2-chlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-yl>-morpholin-4-yl-methanon - 4-brom-5-[4-(2-chlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-(2-methoxy-ethyl)-amid - 4-brom-5-[4-(2,5-dichlor-benzensulfonyl)-piperazin- 1-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2,5-dichlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(lH-benzoimidazol-5-carbonyl)-piperazin-l-yl]-4-bronn-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2,6-dichlor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(2,6-dichlor-benzoyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(2,5-dichlor-benzoyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(3,5-dichlor-benzoyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-methyl-5-[4-(3-trifluormethoxy-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(2-chlor-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(3-chlor-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(2,5-dichlor-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(3-fluor-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-methyl-5-[4-(3-trifluormethyl-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-methyl-5-[4-(3-trifluormethoxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(3-chlor-benzensulfonyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(2,5-dichlor-benzensulfonyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(3-chlor-phenylmethansulfonyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2-chlor-6-fluor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2-chlor-6-fluor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-chlor-phenylmethansulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[l-(3-chlor-benzensulfonyl)-piperidin-4-ylamino]-benzofuran-2-carboxylsyre - 4-brom-5-(3,4-dihydro-lH-isoquinolin-2-yl)-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-chlor-phenoxy)-piperidin-l-yl]-benzofuran-2-carboxylsyre - 4-bronn-5-[4-(4-trifluormethyl-pyrinnidin-2-yloxy)-piperidin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2-fluor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(2-fluor-benzensulfonyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2,6-dichlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(2,6-dichlor-benzensulfonyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2,6-dichlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2,3-dichlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(2,3-dichlor-benzensulfonyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2,3-dichlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2,5-dichlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2,3-dichlor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-methyl-5-[4-(3-tnfluormethyl-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-methyl-5-[4-(2-methyl-l H-benzoimidazol-4-carbonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(2-fluor-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(2-chlor-6-fluor-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(2,6-dichlor-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3,5-dichlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(3,5-dichlor-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3,5-dichlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(3-allyl-2-hydroxy-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(2,3-dimethoxy-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-brom-5-[4-(5-chlor-thiophen-2-ylmethyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-methyl-5-[4-(5-tnfluormethyl-pyndin-2-yloxy)-pipendin-l-yl]-benzofuran-2-carboxylsyre - 4-(2-carboxy-4-cyano-benzofuran-5-yl)-piperazin-l-carboxylsyre-tert-butylester - 4-brom-5-[4-(4-chlor-phenoxy)-piperidin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-ethoxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2-chlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-benzylamid - 5-[4-(3,5-dichlor-2-hydroxy-benzensulfonyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-(4-benzo[l,3]dioxol-4-ylmethyl-piperazin-l-yl)-4-brom-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2,6-dichlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2,4-dichlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(2-allyloxy-benzyl)-piperazin-l-yl]-4-brom-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-tnfluormethyl-phenoxy)-piperidin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(4-tnfluormethyl-phenoxy)-piperidin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-{4-[cyclopropancarbonyl-(2,4-dichlor-phenyl)-amino]-piperidin-l-yl}-benzofuran-2-carboxylsyre - 4-brom-5-{4-[(4-chlor-benzyl)-cyclopropancarbonyl-amino]-piperidin-l-yl>-benzofuran-2-carboxylsyre - 5-{4-[3-(2,6-dichlor-phenyl)-5-isopropyl-isoxazol-4-carbonyl]-piperazin-l-yl)-4-methyl-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2-trifluormethyl-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(3-allyloxy-benzyl)-piperazin-l-yl]-4-brom-benzofuran-2-carboxylsyre - 5-[4-(3-allyl-2-methoxy-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-tert-butyl-2-hydroxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-methyl-5-(4-naphthalen-l-ylmethyl-piperazin-l-yl)-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2-hydroxy-naphthalen-l-ylmethyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2-trifluormethyl-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(3-trifluormethyl-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2,6-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-benzofuran-2-carboxylsyre - {4-brom-5-[4-(2,6-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-benzofuran-2-yl>-morpholin-4-yl-methanon - {4-brom-5-[4-(2,6-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-benzofuran-2-yl>-piperidin-l-yl-methanon - {5-[4-(3,5-dichlor-2-hydroxy-benzensulfonyl)-piperazin-l-yl]-4-methyl-benzofuran-2-yl>-morpholin-4-yl-methanon - {4-brom-5-[4-(2-fluor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-yl>-morpholin-4-yl-methanon - {4-brom-5-[4-(2-chlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-yl>-piperidin-l-yl-methanon - {4-brom-5-[4-(2,6-dichlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-yl>-piperidin-l-yl-methanon - {4-brom-5-[4-(2,6-dichlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-yl>-morpholin-4-yl-methanon - 4-brom-5-[4-(2,6-dichlor-benzoyl)-[l,4]diazepan-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(3-allyl-2-hydroxy-benzyl)-[l,4]diazepan-l-yl]-4-brom-benzofuran-2-carboxylsyre - 5-[4-(3,5-dichlor-2-hydroxy-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-methyl-5-[4-(2,3,6-trichlor-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(2,3-dichlor-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 4-brom-5-{4-[4-brom-5-(4-fluor-2-methoxy-phenyl)-3-methyl-pyrazol-l-yl]-piperidin-l-yl}-benzofuran-2-carboxylsyre - 4-brom-5-{4-[5-(4-fluor-2-methoxy-phenyl)-3-methyl-pyrazol-l-yl]-pipendin-l-yl}-benzofuran-2-carboxylsyre - 4-brom-5-(4-{[(4-chlor-benzyl)-cyclopropylmethyl-annino]-methyl>-pipendin-l-yl)-benzofuran-2-carboxylsyre - {4-brom-5-[4-(2,6-dichlor-benzoyl)-[l,4]diazepan-l-yl]-benzofuran-2-yl}-morpholin-4-yl-methanon - 4-chlor-5-[4-(2,6-dichlor-benzoyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[l-(2,6-dichlor-benzensulfonyl)-pipendin-4-ylamino]-benzofuran-2-carboxylsyre - {4-chlor-5-[4-(2,3-dichlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-yl>-morpholin-4-yl-methanon - {4-brom-5-[4-(2,6-dichlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-yl>-(4-methyl-piperazin-l-yl)-methanon - 4-brom-5-[4-(2,6-dichlor-benzensulfonyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre-(2-dimethylamino-ethyl)-annid - 4-chlor-5-[4-(2-hydroxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - {5-[4-(2,6-dichlor-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-yl}-morpholin-4-yl-methanon - 4-chlor-5-[4-(2,6-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-benzofuran-2-carboxylsyre - 5-[4-(2,3-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-4-methyl-benzofuran-2-carboxylsyre - {5-[4-(2,3-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-4-methyl-benzofuran-2-yl>-morpholin-4-yl-methanon - 4-chlor-5-[4-(2,3-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-benzofuran-2-carboxylsyre - {4-chlor-5-[4-(2,3-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-benzofuran-2-yl}-morpholin-4-yl-methanon - 4-chlor-5-[4-(2,5-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-benzofuran-2-carboxylsyre - {4-chlor-5-[4-(2,5-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-benzofuran-2-yl}-morpholin-4-yl-methanon - 5-[4-(2,5-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-4-methyl-benzofuran-2-carboxylsyre - {5-[4-(2,5-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-4-methyl-benzofuran-2-yl>-morpholin-4-yl-methanon - {4-chlor-5-[4-(2,6-dichlor-benzensulfonyl)-[l,4]diazepan-l-yl]-benzofuran-2-yl>-morpholin-4-yl-methanon - 4-chlor-5-[4-(2-chlor-6-hydroxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2-chlor-6-methoxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(3-ethoxy-2-hydroxy-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2-chlor-3-trifluormethyl-benzyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-{4-[3-(2,6-dichlor-phenyl)-5-isopropyl-isoxazol-4-ylmethyl]-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(2,6-dichlor-benzyl)-piperazin-l-yl]-4-methyl-benzofuran-2-carboxylsyre-amid - 5-[4-(2,6-dichlor-benzyl)-[l,4]diazepan-l-yl]-4-methyl-benzofuran-2-carboxylsyre - {5-[4-(2,6-dichlor-benzyl)-[l,4]diazepan-l-yl]-4-methyl-benzofuran-2-yl}-(4-methyl-piperazin-l-yl)-methanon - {4-brom-5-[4-(2,6-dichlor-benzoyl)-[l,4]diazepan-l-yl]-benzofuran-2-yl}-piperidin-l-yl-methanon - 4-brom-5-[l-(2,6-dichlor-benzoyl)-piperidin-4-ylamino]-benzofuran-2-carboxylsyre - 4-brom-5-[l-(2,3-dichlor-benzoyl)-piperidin-4-ylamino]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2,3-dihydro-indol-l-yl)-piperidin-l-yl]-benzofuran-2-carboxylsyre - 4-[2-(lH-tetrazol-5-yl)-benzofuran-5-yl]-piperazin-l-carboxylsyre-terbutylester - 5-(4-Benzhydryl-piperazin-l-yl)-4-methyl-benzofuran-2-carboxylsyre - 4-brom-5-[4-(2,6-dichlor-benzensulfonylamino)-piperidin-l-yl]-benzofuran-2-carboxylsyre - 4-chlor-5-[4-(2-methyl-5-thiophen-2-yl-2H-pyrazol-3-ylmethyl)-piperazin-l-yl]-benzofuran-2-carboxylsyre - 5-[(lS,4S)-5-(2,6-dichlor-benzensulfonyl)-2,5-diaza-bicyclo[2.2.1]hept-2-yl]-4-methyl-benzofuran-2-carboxylsyre - 5-[4-(2,4-dichlor-phenylcarbamoyl)-piperidin-l-yl]-4-methyl-benzofuran-2-carboxylsyre og de stereoisomeriske former, blandinger af stereoisomeriske former eller farmaceutisk acceptable salte deraf.
2.
Farmaceutisk sammensætning omfattende en forbindelse ifølge krav 1 i blanding med én eller flere farmaceutisk acceptable excipienser. 3. forbindelse ifølge krav 1, til anvendelsen i behandlingen af sygdomme eller lidelser valgt fra hyperkolesterolæmi, hyperlipoproteinæmi, hypertri-glyceridæmi, dyslipidæmi, lipodystrofi, kolestase/fibrose, kolesterol galdestensygdom, gastrointestinal sygdom eller tilstand, hyperglykæmi, diabetes mellitus, type 2 diabetes, insulinresistens, metabolisk infleksibilitet, nefropati, leversygdomme, aterosklerose, cancer, inflammatoriske lidelser, fedme, osteoporose, hudaldring, hårvækstregulering og pigmenteringslidelser, Parkinson's sygdom og/eller Alzheimer's sygdom.
DK09731855.4T 2008-04-18 2009-03-30 Benzofuranderivater som fxr-modulatorer DK2262785T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08300183A EP2110374A1 (en) 2008-04-18 2008-04-18 Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
PCT/EP2009/002297 WO2009127321A1 (en) 2008-04-18 2009-03-30 Benzofurane, benzothiophene, benzothiazol derivatives as fxr modulators

Publications (1)

Publication Number Publication Date
DK2262785T3 true DK2262785T3 (da) 2015-02-16

Family

ID=39769187

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09731855.4T DK2262785T3 (da) 2008-04-18 2009-03-30 Benzofuranderivater som fxr-modulatorer

Country Status (27)

Country Link
US (1) US8575161B2 (da)
EP (2) EP2110374A1 (da)
JP (2) JP5616326B2 (da)
KR (1) KR101662853B1 (da)
CN (1) CN101990535B (da)
AR (1) AR071207A1 (da)
AU (1) AU2009238015B2 (da)
BR (1) BRPI0911243B8 (da)
CA (1) CA2721591C (da)
CO (1) CO6311099A2 (da)
CY (1) CY1116333T1 (da)
DK (1) DK2262785T3 (da)
EA (1) EA020454B1 (da)
EC (1) ECSP10010615A (da)
ES (1) ES2531006T3 (da)
HK (1) HK1155741A1 (da)
HR (1) HRP20150319T1 (da)
IL (1) IL208322A (da)
MX (1) MX2010011292A (da)
MY (1) MY156530A (da)
NZ (1) NZ589327A (da)
PL (1) PL2262785T3 (da)
PT (1) PT2262785E (da)
SI (1) SI2262785T1 (da)
UA (1) UA104140C2 (da)
WO (1) WO2009127321A1 (da)
ZA (1) ZA201008243B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1976828T1 (sl) 2005-12-29 2017-07-31 Celtaxsys, Inc. Diaminski derivati kot inhibitorji levkotrien A4 hidrolaze
EP2110374A1 (en) * 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
WO2010104194A1 (en) 2009-03-10 2010-09-16 Takeda Pharmaceutical Company Limited Benzofuran derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013525489A (ja) 2010-05-06 2013-06-20 ブリストル−マイヤーズ スクイブ カンパニー Ｇｐｒ１１９修飾因子としての二環式ヘテロアリール類似体
EP2566862B1 (en) 2010-05-06 2015-09-16 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
WO2014006637A2 (en) * 2012-07-02 2014-01-09 Symed Labs Limited Improved process for preparing benzofuran-2-carboxamide derivatives
CN102993186B (zh) * 2012-12-20 2015-11-18 北京海步国际医药科技发展有限公司 一种新型的哌嗪衍生物
ES2864862T3 (es) 2013-03-12 2021-10-14 Celltaxis Llc Métodos de inhibición de la leucotrieno A4 hidrolasa
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
AU2014239567B2 (en) 2013-03-14 2017-12-14 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
RU2696559C2 (ru) 2013-03-14 2019-08-05 Селтакссис, Инк. Ингибиторы лейкотриен а4-гидролазы
AU2014320463B2 (en) 2013-09-11 2018-08-02 Centre National De La Recherche Scientifique (Cnrs) Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
MA40814A1 (fr) 2015-02-06 2019-08-30 Intercept Pharmaceuticals Inc Compositions pharmaceutiques pour thérapie combinée
CN107427527B (zh) 2015-03-31 2021-01-26 英安塔制药有限公司 作为fxr/tgr5激动剂的胆汁酸衍生物及其使用方法
KR20170132879A (ko) 2015-04-07 2017-12-04 인터셉트 파마슈티컬즈, 인크. 조합 요법을 위한 약제학적 조성물
CN104926804B (zh) * 2015-06-04 2019-01-25 天津渤海职业技术学院 一类具有抗肿瘤作用的化合物、其制备方法和用途
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
BR112019006651A2 (pt) 2016-10-04 2019-07-02 Enanta Pharm Inc análogos de isoxazol como agonistas de fxr e métodos de uso do mesmo
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
WO2018178260A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
US10898484B2 (en) 2018-05-31 2021-01-26 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
CN113439078B (zh) 2019-02-19 2024-04-23 吉利德科学公司 Fxr激动剂的固体形式
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
JP2022536060A (ja) 2019-05-30 2022-08-12 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁鬱滞性肝疾患の処置で使用するためのｆｘｒアゴニストおよびフィブラートを含む医薬組成物
MX2022000742A (es) 2019-07-18 2022-02-14 Enyo Pharma Metodo para disminuir los efectos adversos del interferon.
EP4090327A1 (en) 2020-01-15 2022-11-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of fxr agonists for treating an infection by hepatitis d virus
CN117202905A (zh) 2021-01-14 2023-12-08 埃尼奥制药公司 Fxr激动剂和ifn用于治疗hbv感染的协同效果
JP2024503861A (ja) * 2021-01-14 2024-01-29 ウエヌイグレックオ・ファーマ 慢性腎疾患を処置する方法
KR20240009411A (ko) * 2021-04-16 2024-01-22 베이징 베스트 패스웨이 매니지먼트 컨설팅 센터 (리미티드 파트너쉽) Fxr 조절인자, 이의 제조 방법, 이의 약제학적 조성물 및 이의 용도
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
CN113214200B (zh) * 2021-05-26 2022-03-29 神隆医药（常熟）有限公司 一种以铜催化偶联反应制备维拉佐酮中间体的方法
WO2023283425A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
WO2023137135A1 (en) * 2022-01-17 2023-07-20 Hepagene Therapeutics (HK) Limited Solid forms of a benzthiazole-piperazinyl-oxazole compound and methods of use thereof
WO2024032530A1 (zh) * 2022-08-11 2024-02-15 江苏恩华药业股份有限公司 芳杂环并环己烷基氨基烷基哌啶衍生物、制备方法及其用途
CN117430574B (zh) * 2023-12-20 2024-03-22 潍坊医学院 一种苯并呋喃衍生物及其制备方法、用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006524A1 (de) * 1978-06-22 1980-01-09 Ciba-Geigy Ag Neue Tetrahydropyridin- und Piperidinderivate und deren Säureadditionssalze, Verfahren zu deren Herstellung und solche enthaltende pharmazeutische Zusammensetzungen
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
US5706833A (en) * 1993-07-13 1998-01-13 Daicel Chemical Industries, Ltd. Tobacco filters and method of producing the same
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
AU5928898A (en) 1997-01-24 1998-08-18 Regents Of The University Of California, The Use of fxr, pparalpha and lxralpha activators to restore barrier function, promote epidermal differentiation and inhibit proliferation
WO1998041519A1 (en) 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
AU749271B2 (en) 1997-07-01 2002-06-20 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU8127998A (en) 1997-07-11 1999-02-08 Japan Tobacco Inc. Quinoline compounds and medicinal uses thereof
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
US6071955A (en) 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
WO2000058360A2 (en) 1999-03-29 2000-10-05 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
AU4055400A (en) 1999-04-02 2000-10-23 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
CA2373892A1 (en) 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003505435A (ja) 1999-06-04 2003-02-12 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体ゴニストとしての置換ピペリジン
DE19932314A1 (de) * 1999-07-10 2001-01-11 Merck Patent Gmbh Benzofuranderivate
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
RU2269354C2 (ru) 1999-09-28 2006-02-10 Байер Корпорейшн Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения
DE19958496A1 (de) * 1999-12-04 2001-06-07 Merck Patent Gmbh Verfahren zur Herstellung von 5-(1-Piperazinyl)-benzofuran-2-carboxamid durch Übergangsmetallkatalysierte Aminierung
AU4929601A (en) 2000-03-23 2001-10-03 Merck & Co Inc Substituted piperidines as melanocortin receptor agonists
EP1268000A4 (en) 2000-03-23 2004-12-29 Merck & Co Inc SPIROPIPERID DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS
WO2001082917A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
SK10802003A3 (sk) 2001-02-02 2004-05-04 Takeda Chemical Industries, Ltd. Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok
CN1633297A (zh) 2001-02-28 2005-06-29 麦克公司 作为黑皮质素－4受体激动剂的酰化哌啶衍生物
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
CZ2003698A3 (cs) 2001-03-22 2003-06-18 Solvay Pharmaceuticals B. V. 4,5-Dihydro-1H-pyrazolové deriváty mající CB1-antagonistickou účinnost
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002344820B2 (en) 2001-06-20 2006-12-14 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
US7253172B2 (en) 2001-06-20 2007-08-07 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
US6674272B2 (en) 2001-06-21 2004-01-06 Champion Microelectronic Corp. Current limiting technique for a switching power converter
JP4357293B2 (ja) 2001-06-27 2009-11-04 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
DE60223920T2 (de) 2001-06-27 2008-11-13 Smithkline Beecham Corp. Pyrrolidine als dipeptidyl-peptidase-inhibitoren
WO2003002531A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003002593A2 (en) 2001-06-27 2003-01-09 Probiodrug Ag Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
ATE388951T1 (de) 2001-07-03 2008-03-15 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
KR20020082826A (ko) * 2002-10-12 2002-10-31 박선희 한약재를 이용한 기능성피자의 제조방법
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
JP2009519290A (ja) * 2005-12-15 2009-05-14 エフ．ホフマン−ラ ロシュ アーゲー ピロロ［２，３−ｃ］ピリジン誘導体
EP1963331A1 (en) 2005-12-15 2008-09-03 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
EP2110374A1 (en) * 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators

Also Published As

Publication number Publication date
KR101662853B1 (ko) 2016-10-05
UA104140C2 (en) 2014-01-10
MY156530A (en) 2016-02-26
IL208322A (en) 2016-02-29
WO2009127321A1 (en) 2009-10-22
EP2262785B1 (en) 2015-01-14
ECSP10010615A (es) 2010-12-30
PT2262785E (pt) 2015-04-29
CN101990535A (zh) 2011-03-23
US20110105475A1 (en) 2011-05-05
AU2009238015A1 (en) 2009-10-22
CY1116333T1 (el) 2017-02-08
NZ589327A (en) 2012-06-29
JP5997730B2 (ja) 2016-09-28
MX2010011292A (es) 2010-11-10
EA020454B1 (ru) 2014-11-28
BRPI0911243B1 (pt) 2019-10-08
HK1155741A1 (en) 2012-05-25
HRP20150319T1 (hr) 2015-06-19
CO6311099A2 (es) 2011-08-22
AU2009238015B2 (en) 2013-09-12
CA2721591A1 (en) 2009-10-22
EP2262785A1 (en) 2010-12-22
CA2721591C (en) 2016-08-09
BRPI0911243B8 (pt) 2021-05-25
SI2262785T1 (sl) 2015-05-29
IL208322A0 (en) 2010-12-30
JP5616326B2 (ja) 2014-10-29
AR071207A1 (es) 2010-06-02
CN101990535B (zh) 2013-06-19
ES2531006T3 (es) 2015-03-09
EA201001647A1 (ru) 2011-06-30
US8575161B2 (en) 2013-11-05
EP2110374A1 (en) 2009-10-21
BRPI0911243A2 (pt) 2015-10-06
JP2011516589A (ja) 2011-05-26
JP2014237676A (ja) 2014-12-18
ZA201008243B (en) 2012-04-25
KR20110002478A (ko) 2011-01-07
PL2262785T3 (pl) 2015-04-30

Similar Documents

Publication Publication Date Title
DK2262785T3 (da) Benzofuranderivater som fxr-modulatorer
CA2785340C (en) Substituted isoquinolinones and quinazolinones
AU2008276236B2 (en) Compounds and methods for modulating FXR
US20090286791A1 (en) Amide Compounds
WO2013036912A2 (en) Amido compounds as rorϒtmodulators and uses thereof
KR20100087220A (ko) Ｐａｒｐ 억제제로서의 피리다지논 유도체
WO2007055418A1 (ja) アザ置換スピロ誘導体
MX2007001106A (es) Derivados de piperazina utiles para el tratamiento de trastornos gastrointestinales.
WO2010034649A1 (en) 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases
KR20100114021A (ko) 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
TW201020234A (en) 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives
JP2010536842A (ja) ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのキノリン−４−オン及び４−オキソジヒドロシンノリン誘導体
JPWO2012020780A1 (ja) 複素環化合物およびその用途
CA2727669C (fr) Nouveaux derives de (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
KR102542698B1 (ko) 신규한 벤조사이오펜 유도체 및 bet 억제제로서의 용도
JP6471153B2 (ja) アルドステロン合成酵素阻害剤としての新規フェニルジヒドロピリジン誘導体
WO2015162452A1 (en) Substituted pyrazole compounds as cb1 receptor antagonists and uses thereof
Zhao et al. Design, synthesis and evaluation of 1-benzyl-1H-imidazole-5-carboxamide derivatives as potent TGR5 agonists
CN103958466A (zh) 作为crth2拮抗剂的含氮并环化合物
JP2000319166A (ja) 腸溶製剤
TW201029996A (en) Heterocyclic compound